GKOS Glaukos Corporation

  1. Stocks
  2. Healthcare
  3. NYSE: GKOS

Price (delayed)

$153.49

Market cap

$9.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.26

Enterprise value

$9.04B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 21

Glaukos ( www.glaukos.com ) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos ...

Highlights
The revenue has grown by 42% YoY and by 11% from the previous quarter
The company's gross profit rose by 17% QoQ and by 13% YoY
The gross margin has contracted by 20% YoY but it has grown by 5% from the previous quarter
Glaukos's net income has shrunk by 103% YoY
Glaukos's EPS has plunged by 99% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.glaukos.com
Peers: IART ICUI

Key stats

What are the main financial stats of GKOS

GKOS stock price

How has the Glaukos stock price performed over time
Intraday
-3.98%
1 week
-6.11%
1 month
-16.98%
1 year
81.24%
YTD
35.94%
QTD
9.82%

Financial performance

How have Glaukos's revenue and profit performed over time
Revenue
$612.84M
Gross profit
$372.02M
Operating income
-$193.36M
Net income
-$188.05M
Gross margin
60.7%
Net margin
-30.7%
Glaukos's net income has shrunk by 103% YoY
GKOS's operating income has shrunk by 100% YoY but it is up by 2.7% QoQ
The net margin has decreased by 43% YoY but it has increased by 10% QoQ
The revenue has grown by 42% YoY and by 11% from the previous quarter

Price vs fundamentals

How does GKOS's price correlate with its fundamentals

Growth

What is Glaukos's growth rate over time

Valuation

What is Glaukos stock price valuation
P/E
N/A
P/B
13.21
P/S
14.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.75
Glaukos's EPS has plunged by 99% YoY
The price to book (P/B) is 88% more than the 5-year quarterly average of 7.3 and 48% more than the last 4 quarters average of 9.3
Glaukos's equity has decreased by 11% YoY
The revenue has grown by 42% YoY and by 11% from the previous quarter
The P/S is 29% higher than the last 4 quarters average of 11.9 and 28% higher than the 5-year quarterly average of 12.0

Efficiency

How efficient is Glaukos business performance
The ROE has plunged by 117% YoY and by 2.3% from the previous quarter
The return on assets has dropped by 111% year-on-year
The ROIC has dropped by 101% year-on-year but it is up by 2.8% since the previous quarter
Glaukos's ROS has plunged by 54% YoY but it has increased by 11% from the previous quarter

Dividends

What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GKOS.

Financial health

How did Glaukos financials performed over time
GKOS's current ratio is down by 9% year-on-year and by 7% since the previous quarter
The quick ratio has contracted by 9% YoY and by 7% from the previous quarter
The debt is 85% lower than the equity
Glaukos's equity has decreased by 11% YoY
The debt to equity has grown by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.